日本人2型糖尿病患者におけるインクレチン関連薬の食事摂取量への影響

基本情報

NCT ID

NCT01568125

ステータス

不明

試験のフェーズ

-

試験タイプ

観察

目標被験者数

100

治験依頼者名

Nagaoka Red Cross Hospital

概要

It is well known that incretin, particular GLP-１enhances satiety and reduces energy intake in controlling appetite and dietary in humans (Flint A, et al. Gutzwiller JP et al.). Recently, incretin-based therapy has been attracted a lot of interest (Hare KJ, Knop FK). However, it is not clear how the incretin-based therapy affects energy and content of dietary intake in patients with type 2 diabetes mellitus (T2DM). Previously, the investigators reported the amount of energy and content of dietary intake in type 2 diabetic Japanese patients with more than 10 years of long time duration after discovery using questionnaire (Inoue K et al.) and the patients were impaired a secretion of active GLP-1 (Kamoi et al). The investigators examine whether the incretin-based therapy effects on the energy and content of dietary intake in the same patients before and one year after administration of incretin-related drugs using the same method previously (Inoue K et al.).

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)